Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
06 September 2023 - 12:59PM
Business Wire
Company-Sponsored Educational Events Will
Feature Latest Surgical Technologies, Including the SeeLuma™ Fully
Digital Surgical Visualization Platform, MIMS® and the IC-8®
Apthera IOL
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
health company dedicated to helping people see better to live
better, today announced 13 podium and poster presentations during
the European Society of Cataract and Refractive Surgery (ESCRS)
annual meeting, which will take place in Vienna Sept. 8-12,
2023.
The presentations will include:
- A three-year analysis of the superonasal minimally invasive
micro sclerostomy (MIMS) surgical treatment for open angle
glaucoma*
- Interim results of surgical procedures that used MINT™
(Minimally Invasive Nasal Trabeculostomy) in open angle glaucoma
patients
- An evaluation of visual outcomes in patients with complex
corneas who were implanted with the IC-8 Apthera intraocular lens
(IOL)
- Clinical outcomes of the LuxSmart™ toric IOL
- Safety and performance results of the enVista® ENVY, an
investigational premium IOL
- Refractive outcomes of a low 0.90 diameter cylinder for the
investigational enVista Toric IOL.
Bausch + Lomb will also host several educational and networking
events during the meeting. Educational events will include a MIMS
masterclass and a panel of distinguished physicians who will
provide insights from their firsthand clinical experience using the
company’s newly launched SeeLuma Fully Digital Surgical
Visualization Platform. Other presentations featuring the company’s
latest surgical technology will take place in the Bausch + Lomb
booth, and Bausch + Lomb will host a Lift Off Celebration event to
mark its 170th anniversary.
Following is the list of key scientific podium and e-poster
presentations, as well as details for the featured educational
events:
Podium Presentations
- “Evaluating the Range of Vision with a Small Aperture IOL in
Patients Previously Treated with a Monofocal IOL in the Other Eye.”
S. Bafna et al.
- “Evaluation of the Safety and Performance of a Novel One-Piece
Hydrophobic Acrylic Trifocal Intraocular Lens: Results from a
Prospective, Multicentre Clinical Trial.” P. Harasymowycz et
al.
- “Evaluation of Visual Outcomes in Patients with Complex Corneas
Implanted with the IC-8 IOL.” J. Mehta et al.
- “Prospective Study of Small Aperture IOL Implantation in Eyes
with Previous Refractive Procedures.” R.E. Ang et al.
Poster Presentations
- “Clinical Outcomes After Bilateral Implantation of The Enhanced
Depth of Focus LuxSmart Intraocular Lenses.” W. Lubiński et al
- “Clinical Outcomes of a Toric Extended Range of Vision
Intraocular Lens Based on the Combination of Fourth- and
Sixth-Order Spherical.” R. Ruiz-Mesa et al.
- “Comparison of Two Extended Range of Focus Intraocular Lenses:
Vivity Vs. Luxsmart.” J. Hugues et al.
- “Retinal Visualization in a Small Aperture IOL Treated Eyes.”
M. Blecher et al.
- “Visual Performance of Ultra-Low Cylinder Powered (0,90) Toric
IOL Compared to Non-Toric.” A. Muzychuk et al.
- “Minimally Invasive Micro Sclerostomy: 3 Years Follow Ups.” L.
Voskanyan et al.
- “Trabeculostomy as a New Effective Surgery for Glaucoma.” L.
Voskanyan et al.
- “Acufocus IC-8 Implantation During Cataract Surgery in
Irregular Corneas.” C. Hubert et al
- “Visual Outcomes Following Implantation of Small Aperture
Intraocular Lens in Patients with Irregular Corneas.” U. Bhatt
Featured Educational Events Friday,
September 8
- “MIMS Masterclass” 5:30-7:30 p.m. CEST at Palais Palffy,
Josefsplatz 6, Vienna Professor Anselm Jünemann, Dr. Imran Masood,
Professor Luis Pablo and Dr. Lilit Voskanyan will present their
experiences with the MIMS surgical treatment for open angle
glaucoma.
Saturday, September 9
- “New Dimensions in Visualization: Changing the Way You Look
& Your Patients See” 1:00-2:00 p.m. CEST at Messe Wien
Exhibition & Congress Centre, Room A7, Vienna Professor
Burkhard Dick will lead an engaging conversation with an
international panel of surgeons, including Drs. Robert Ang, Alain
Saad and Adam Muzychuk, who will share their surgical experiences
using the IC-8 Apthera IOL, SeeLuma Fully Digital Visualization
Platform and Stellaris Elite™ Phacoemulsification System,
respectively.
Saturday, September 9 and Sunday,
September 10
- "Meet the Expert” 9:30 a.m.-4:30 p.m. CEST at Messe Wien
Exhibition & Congress Centre, booth #B203, Vienna Surgeons will
share their surgical experiences using the LuxSmart™ IOL, IC-8
Apthera IOL, SeeLuma Fully Digital Visualization Platform,
Stellaris Elite and the refractive SUPRACOR™ and transepi PRK
procedures.
Sunday, September 10
- “Lift Off Celebration” 6:30-10:30 p.m. CEST at Palais Ferstel,
Strauchgasse 4, Vienna ESCRS attendees are invited to celebrate
Bausch + Lomb’s 170th anniversary.
For more information, visit
https://events.bauschsurgical.eu/escrs/.
About Bausch + Lomb Bausch + Lomb is dedicated to
protecting and enhancing the gift of sight for millions of people
around the world – from the moment of birth through every phase of
life. Its comprehensive portfolio of more than 400 products
includes contact lenses, lens care products, eye care products,
ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with approximately 13,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario with corporate offices in
Bridgewater, New Jersey. For more information, visit www.bausch.com
and connect with us on Twitter, LinkedIn, Facebook and
Instagram.
Forward-looking Statements This news release may contain
forward-looking statements, which may generally be identified by
the use of the words “anticipates,” “hopes,” “expects,” “intends,”
“plans,” “should,” “could,” “would,” “may,” “believes,”
“estimates,” “potential,” “target,” or “continue” and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch + Lomb’s filings with
the U.S. Securities and Exchange Commission and the Canadian
Securities Administrators, which factors are incorporated herein by
reference. Readers are cautioned not to place undue reliance on any
of these forward-looking statements. These forward-looking
statements speak only as of the date hereof. Bausch + Lomb
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this news release or to reflect actual outcomes, unless required by
law.
*Bausch + Lomb exclusively distributes MIMS in Europe through a
strategic agreement with Sanoculis.
© 2023 Bausch + Lomb.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906824036/en/
Media Contacts: Lainie Keller lainie.keller@bausch.com
(908) 927-1198
Kristy Marks Kristy.marks@bausch.com (908) 927-0683
Investor Contacts: George Gadkowski
george.gadkowski@bausch.com (877) 354-3705 (toll free) (908)
927-0735
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024